DIRECTOR
Mark Tuszyński, MD, PhD  San Diego, CA

PROGRAM DESCRIPTION
Proteinopathies are diseases that result from disorders of protein synthesis, trafficking, folding, processing, or degradation in cells. An exciting new body of research suggests that proteinopathies may constitute prime mechanisms for neurodegeneration of neurons in Parkinson’s disease, Alzheimer’s disease, ALS, Huntington’s, and other disorders. Moreover, proteinopathies may provide mechanisms for spread of these diseases through the brain. This session will review work in proteinopathies and how this knowledge is leading to new therapies.

LEARNING OBJECTIVES
Upon completion, participants should be able to understand what proteinopathies are, how they relate to neurological disorders, and how they are being targeted in the development of new therapeutics.

RECOMMENDED AUDIENCE
Clinicians and Researchers Interested in Basic Disease Mechanism and Therapeutic Development

SCHEDULE

1:00  Introduction
Mark Tuszyński, MD, PhD  San Diego, CA

1:05  Proteinopathy Mechanisms in Models in ALS
Aaron Gitler, PhD  Stanford, CA

1:55  Proteinopathy Mechanisms in Models in Parkinson’s Disease
Eliezer Masliah, MD  San Diego, CA

2:45  Break

3:00  Proteinopathy Mechanisms in Models in Tauopathies
Marc Diamond, MD  St. Louis, MO

3:50  Panel Discussion
Faculty

3 CME
Friday, January 23
1:00 p.m.–4:00 p.m.